Company intelligence / Profile preview

ViroVax LLC

Lawrence, Kansas, United States

Ownership: Private
Development stage: Other

Overview

ViroVax develops vaccines, adjuvants, and therapeutics for infectious diseases; licensed adjuvant Alhydroxiquim-II for COVAXIN (India's COVID-19 vaccine in Phase I/II trials as of 2020); evaluating subunit COVID-19 vaccine and antivirals with NIH support

Therapeutic areas: Infectious Diseases
Modalities: VaccineAdjuvant
Industry: Biotech

Drug pipeline

2 assets

C1-produced ferritin nanoparticle Mpox antigen vaccine

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Bharat Biotech International Limited

Beyond the preview

Go deeper on ViroVax LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ViroVax LLC.

Explore the full profile